Stephanie Price

A new brainwave analysis solution is aiming to transform cannabis and mental health research by analysing the effects of different medicines on the brain.

ActivePure is aiming to revolutionise how environments from hospitals to elite sports facilities stay clean with its air purification system.

Last month, the Dutch State Commission on MDMA released its report advising the Government to allow access to MDMA-Assisted Therapy (MDMA-AT) for people living with PTSD. The report has now been translated into English.

On August 9 the U.S Food and Drug Administration rejected Lykos Therapeutics' New Drug Application (NDA) for MDMA-assisted psychotherapy. However, the journey to approval is not over yet, and Lykos is now working to address the issues that led to the rejection.

Drug Science and University College London (UCL) are joining forces in a new collaboration that seeks to address concerns over the therapy component of MDMA-assisted psychotherapy in light of the recent U.S. Food and Drug Administration (FDA) rejection.

A damning report into the state of the NHS has called for a major overhaul, highlighting how technology in the service lags 15 years behind the private sector.

New research used intracranial electroencephalography (icEEG) tests – where small electrodes are inserted into the substance of the brain to measure electrical impulses – to track the brain activity of nine patients being evaluated for surgical treatment of medication-resistant epilepsy.

A first-of-its-kind study has revealed that millions of Americans could benefit from psilocybin therapy if approved by the U.S. Food and Drug Administration.

A six-month follow-up study of a Phase 2 clinical trial investigating psilocybin versus escitalopram for the treatment of major depressive disorder has shown positive results.

For the first time, a government-funded UK trial will investigate psilocybin-assisted psychotherapy for targetting relapses associated with opioid addiction, aiming to bring an innovative new therapy to the NHS if successful.